Syngenta Releases Innovotech from Right of First Refusal Obligation

Innovotech Inc. (TSX VENTURE:IOT), a pioneer in the field of biofilm product
development, today announced that Syngenta AG has decided not to pursue its
Right of First Refusal for Innovotech's seed treatment product, Agress(R).


"Agress(R) continues to show excellent results in recently completed field
trials that expand its potential uses to high-value added crops such as fruits,
vegetables and pulses," said Ken Boutilier, President and CEO of Innovotech.
"While we are disappointed with this decision, the fact remains that Agress(R)
has consistently shown that it is highly effective as a treatment for
controlling seed-borne pathogens and as a plant spray. As such, we look forward
to working with other industry participants who have expressed interest, as we
continue to seek regulatory approval from the US Environmental Protection
Agency."


Agress(R) addresses some major problems in agricultural crop protection related
to the use of the important antibiotic Streptomycin for the treatment of crop
diseases. Firstly, Streptomycin is used in human health and its use in
agriculture has been banned in many countries, including Canada. Furthermore, in
many regions where Streptomycin is used to manage crop diseases, microbial
resistance to the antibiotic is becoming increasingly prevalent, making it an
ineffective disease management option in those regions. Agress(R) has shown to
be at least as effective as Streptomycin in preventing a number of bacterial
diseases, without the environmental consequences.


About Innovotech Inc.

Innovotech Inc. is a pioneer in the field of biofilm product development,
focused on providing innovative and practical solutions to medical, agricultural
and industrial problems caused by microbial biofilms. Biofilms are organized
communities of microorganisms that exist in virtually every natural environment
and are responsible for a host of diseases in human health, animal health and
agriculture. There are few products or regulatory standards, aside from those of
Innovotech, designed specifically for biofilm-forming organisms. 


Innovotech has a broad range of products that address the issue of biofilms
within a number of different industries, including commercially available
products in three market segments; the MBEC Assay(TM), bioFILM PA(TM) and
InnovoSCEPT veterinary kits. The MBEC Assay(TM) is a high throughput biofilm
growth device that was recently approved as an ASTM International standard.
bioFILM PA(TM) is the first diagnostic test to assist physicians in the
selection of the most effective combination antibiotic treatment of patients
with biofilm-based chronic lung infections, while the InnovoSCEPT veterinary
tests are designed to determine the most effective antibiotic treatment for
infections in both large and small animals. 


Innovotech also has three products in advanced stages of development;
InnovoSCEPT human tests have been designed specifically to address antibiotic
treatment for human infections, Agress(R) is a unique, environmentally friendly
seed treatment and plant spray designed to protect crops against both bacterial
and fungal infections and Sani-Lux(TM) is a light-activated, natural hard
surface sanitizer.


Connect with us:

Website: www.innovotech.ca

Blog: www.cf-test.ca

Twitter:www.twitter.com/innovotech

Facebook:www.facebook.com/innovotech

This document may contain forward-looking statements that are predictive in
nature and subject to risks and uncertainties that cannot be predicted or
quantified; consequently, actual results may differ materially from past results
and those expressed or implied by any forward-looking statements. Factors that
could cause or contribute to such risks or uncertainties include, but are not
limited to: the regulatory environment including the difficulty of predicting
regulatory outcomes; changes in the value of the Canadian dollar; the Company's
reliance on a small number of customers including government organizations;
fluctuations in operating results; government policies or actions; progress and
cost of clinical trials; reliance on key strategic relationships; uncertainty
related to intellectual property protection and potential costs associated with
its defense; the Company's exposure to lawsuits and other matters beyond the
control of management. Should known or unknown risks or uncertainties
materialize, or should management's assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company undertakes no
obligation to publicly make or update any forward-looking statements, except as
required by applicable law.
Innovotech (TSXV:IOT)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024